Stockhub

Galmed Pharmaceuticals Ltd.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

12 August 2022

7 August 2022

  • curprev 10:1710:17, 7 August 2022 >Paris 1,230 bytes +1,230 Created page with "Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associat..."
Retrieved from "https://stockhub.co/research/Galmed_Pharmaceuticals_Ltd."